While the historical EPS growth rate for Cambium is 3.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 96.4% this year, crushing the industry average, ...

Cambium (CMBM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 Day CMBM -3.39% DJIA 0.37% Russell 2K 1.18% Technology -0.28% ...

Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical ...

Samsung Electronics Co. Ltd.-0.19% ₩355.59T ...

Meet the Chef with Alistair Craig of The Terrace Restaurant and Monty's Inn at The Montagu Arms Hotel in Beaulieu.

Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent ...

Threat actors are exploiting an unspecified zero-day vulnerability in Cambium Networks cnPilot routers to deploy a variant of ...